Park, J.Y., Kim, B.G., Kim, J.S. and Hwang, J.H. (2018) Matrix Metalloproteinase 9 Point-of-Care Immunoassay Result Predicts Response to Topical Cyclosporine Treatment in Dry Eye Disease. Translational Vision Science & Technology, 7, 31-34.
https://doi.org/10.1167/tvst.7.5.31

has been cited by the following article:

• TITLE: Efficacy of Isotonic Seawater Solution on Inflammation of the Ocular Surface in Matrix Metalloproteinase MMP-9-Positive Dry Eye Disease Patients

  AUTHORS: Diaz-Llopis Manuel, Pinazo-Duran Maria Dolores, Diaz-Guiñon Loreto, Rahhal-Ortuño Miriam, Gallego-Pinazo Roberto, Dolz-Marco Rosa, Diaz-Guiñon Teresa, Diaz Maria, Romero Francisco Javier

  KEYWORDS: Dry Eye, Inflammadry Test, MMP-9, Ocular Surface Inflammation, Ophthal-mic Isotonic Seawater Solution

  JOURNAL NAME: Open Journal of Ophthalmology, Vol.10 No.3, August 6, 2020

  ABSTRACT: Purpose: Prospective study to evaluate the anti-inflammatory efficacy of isotonic seawater solution on metalloproteinase 9 (MMP-9) levels in the tears of patients with dry eye disease (DED). Methods: A total of 50 patients were included, with the following dry eye criteria in both eyes: InflammaDry? test initially positive, ocular surface disease index (OSDI) score ≥ 12 and Results: The InflammaDry test was positive in 100% of the patients (n = 50) and in 100% (n = 100) of the eyes before treatment. In 14 (28%) patients the test became negative in both eyes, and in 15 (30%) it was negative in one of the eyes. In 43% (n = 43) of the positive eyes, MMP-9 became undetectable in the tear fluid following treatment with isotonic seawater. This change was statistically significant (p Conclusions: The washes with ophthalmic isotonic seawater solution have a significant impact on inflammation of the ocular surface in dry eye disease, with an ability to make MMP-9 levels negative in 43% of cases.